What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• The FDA has been cracking down on pharmacies that make and sell compounded copies of GLP‑1 drugs (semaglutide, tirzepatide, etc.) outside of the law — especially those producing bulk, prefilled vials/cartridges or selling directly to consumers without valid patient‑specific prescriptions. The agency issued warning letters, consumer alerts and asked state boards and prosecutors to act in multiple cases during 2023–2024.
• That doesn’t mean all compounding stopped. Compounding is still legal in specific circumstances: (1) 503A state‑licensed pharmacies that compound only in response to a valid prescription for an individually identified patient, and (2) FDA‑registered 503B “outsourcing facilities” that follow current Good Manufacturing Practices (CGMP) and the FDA’s rules — but both types have limits, and FDA has said many compounded GLP‑1 products are not acceptable.

What the FDA objected to

• The core issue: compounding pharmacies were making products that are essentially copies of FDA‑approved drugs (Ozempic/Wegovy, Mounjaro/Zepbound, etc.) and distributing them widely or selling prefilled doses without individualized prescriptions. Under the Federal Food, Drug, and Cosmetic Act the FDA generally disallows large‑scale compounding of copies of approved drugs and compounding without patient‑specific orders.
• The FDA warned about safety/quality risks (sterility, potency, contamination, inaccurate dosing) and legal violations, and it sent warning letters and pursued enforcement against specific operations that appeared to be operating like unlicensed manufacturers.

Who can still operate legally (and what that means)

• 503A compounding pharmacies (state‑licensed):
  • Can legally compound drugs when a licensed prescriber issues a valid prescription for an individual patient.
  • Cannot legally mass‑produce or sell compounded GLP‑1s as ready‑to‑dispense products to the general public.
• 503B outsourcing facilities (FDA registered):
  • May manufacture larger batches for hospitals/clinics if they register with FDA and comply with CGMP and other requirements.
  • However, FDA policy limits compounding of products that are “essentially copies” of approved drugs except in narrow circumstances (e.g., drug shortage).
• Retail pharmacies filling an FDA‑approved GLP‑1 product (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus) with a prescription are fully legal — and generally the safest option because the product is manufactured, labeled, and tested under FDA oversight.

Practical consumer guidance

• Prefer FDA‑approved products from established manufacturers: Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound). Those have known dosing, labeling, and manufacturing controls.
• If you are considering a compounded version:
  • Make sure there is a valid, individualized prescription addressed to a named patient.
  • Ask whether the pharmacy is a state‑licensed 503A or an FDA‑registered 503B facility. For 503B facilities, you can check FDA’s list of registered outsourcing facilities on the FDA website.
  • Request certificates of analysis, sterility testing results, and lot records. Ask how the product is stored and shipped.
  • Avoid companies that will sell prefilled doses or cartridges without asking for a patient‑specific prescription.
• Be cautious buying from online or overseas sellers; quality and legal status can be very uncertain.

If you want, I can:

• Look up whether a particular compounding pharmacy is registered as a 503B (if you give the name), or
• Point you to the FDA pages that list registered outsourcing facilities and the agency’s consumer warnings about compounded GLP‑1s.